EUVIMEDOpdag EUVIMED
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity

Marije B Overdijk iD, Kristin Strumane iD, Ruth Plummer iD, Patricia LoRusso iD, Jordi Rodon Ahnert iD, Udai Banerji iD, Elena Garralda iD, Emiliano Calvo iD, Han Si, Naomi Hoevenaars iD, Jens Thing Mortensen, Sieto Bosgra iD and 8 more

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70546 ↗

At a glance

Klinische Studie (Phase II) in Clinical and Translational Science, 2026. Written by Marije B Overdijk and 19 co-authors. Institution: Genmab B.V., Utrecht, the Netherlands. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Chemical and Drug Induced Liver Injury, Neoplasms, Receptors, TNF-Related Apoptosis-Inducing Ligand. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

HexaBody‐DR5/DR5 (GEN1029) is a death receptor 5 (DR5) agonist composed of two humanized immunoglobulin G1 (IgG1) antibodies, Hx‐DR5‐01 and Hx‐DR5‐05, that bind non‐overlapping DR5 epitopes with nanomolar affinity. HexaBody‐DR5/DR5 is designed to activate the TRAIL pathway through DR5 clustering. This phase 1/2a, open‐label, multi‐center study aimed to determine the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of HexaBody‐DR5/DR5 in patients with advanced solid tumors. In the study, 46 patients received biweekly intravenous injections of HexaBody‐DR5/DR5 at doses ranging from 0.1 to 3.0 mg/kg, including patients with colorectal, gastric, non‐small‐cell lung, pancreatic, and triple‐negative breast cancer. Safety evaluations revealed that 76.1% of patients experienced at least one grade (G) ≥ 3 treatment‐emergent adverse event (TEAE), and 45.7% had drug‐related G ≥ 3 events. The most frequent G ≥ 3 drug‐related TEAEs were elevations of liver transaminases and diarrhea. According to RECIST criteria, 32.6% of patients showed stable disease. No patients achieved a partial or complete response. Exploratory assessments of cleaved cytokeratin 18 (cCK18) plasma levels indicated apoptotic pathway activation upon treatment. Reductions in circulating tumor DNA (ctDNA) levels and tumor metabolic activity according to PERCIST criteria suggested tumor‐targeted biological activity. Nonclinical studies in vitro using human liver models demonstrated that HexaBody‐DR5/DR5 directly inhibits viability of hepatocytes, but not Kupffer cells. The non‐clinical liver toxicity was driven by dual epitope binding and hexamerization features, independent of FcγR‐mediated crosslinking. Overall, these findings suggest that the TRAIL pathway has potential as a target for cancer therapy, provided tumor‐specificity is sufficiently high to achieve an acceptable therapeutic index.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedChemical and Drug Induced Liver InjuryNeoplasmsReceptors, TNF-Related Apoptosis-Inducing LigandAdultAgedAnimalsFemaleHumansMaleMiddle AgedApoptosisLiver

Author keywords

agonistapoptosisdeath receptormonoclonal antibodiestumor

Substances

Antibodies, Monoclonal, HumanizedReceptors, TNF-Related Apoptosis-Inducing LigandTNFRSF10B protein, human

Authors and institutions

  • Genmab B.V., Utrecht, the Netherlands.
  • Newcastle University Translational and Clinical Research Institute, Medical School, Newcastle University, Newcastle upon Tyne, UK.
  • Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
  • Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Institute of Cancer Research and the Royal Marsden, London, UK.
  • Early Drug Development Unit, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

ORCID profiles: Marije B Overdijk, Kristin Strumane, Ruth Plummer, Patricia LoRusso, Jordi Rodon Ahnert, Udai Banerji, Elena Garralda, Emiliano Calvo, Naomi Hoevenaars, Sieto Bosgra, Panagiota Diamantopoulou Reiter, Maria Jure-Kunkel

Cite

APA

Overdijk, M. B., Strumane, K., Plummer, R., LoRusso, P., Rodon Ahnert, J., Banerji, U., Garralda, E., Calvo, E., Si, H., Hoevenaars, N., Mortensen, J. T., Bosgra, S., Malmberg, A., Ellekilde-Pedersen, M., Ramirez-Andersen, T., Diamantopoulou Reiter, P., Favaro, E., Forssmann, U., Breij, E. C. W., & Jure-Kunkel, M. (2026). Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity. Clinical and Translational Science. https://doi.org/10.1111/cts.70546

Vancouver

Overdijk MB, Strumane K, Plummer R, LoRusso P, Rodon Ahnert J, Banerji U, et al. Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity. Clinical and Translational Science. 2026. doi:10.1111/cts.70546

BibTeX
@article{Overdijk2026,
  author = {Overdijk, Marije B and Strumane, Kristin and Plummer, Ruth and LoRusso, Patricia and Rodon Ahnert, Jordi and Banerji, Udai and Garralda, Elena and Calvo, Emiliano and Si, Han and Hoevenaars, Naomi and Mortensen, Jens Thing and Bosgra, Sieto and Malmberg, Anders and Ellekilde-Pedersen, Merete and Ramirez-Andersen, Teresa and Diamantopoulou Reiter, Panagiota and Favaro, Elena and Forssmann, Ulf and Breij, Esther C W and Jure-Kunkel, Maria},
  title = {Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70546}
}
Start for free →